Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H in Lymphoplasmacytic Lymphoma
NCT00142181Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2003
- Primary completion
- Oct 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Mar 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00142181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142181.